Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2012. The report serves as a notification of a specific corporate governance change rather than a financial results announcement.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. No financial data is included in this specific report.
Material Changes
The primary material change disclosed is a directorship update: Sir Robert Wilson, a Non-Executive Director of GlaxoSmithKline plc, stepped down as Non-Executive Chairman of BG Group plc effective May 16, 2012.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, contingencies, or unusual items. The document is strictly a director declaration pursuant to Listing Rule 9.6.14.
Key Facts for Investors to Verify
- Sir Robert Wilson's resignation from the Non-Executive Chairman role at BG Group plc.
- The effective date of the resignation (May 16, 2012).
- Confirmation that this filing does not contain financial performance data for the period.